Important milestones in acute leukemia in 2013

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• The 7+3 chemotherapy regimen for acute myeloid leukemia (AML) was established 40 years ago.
• Hematopoietic cell transplantation has evolved from a rare procedure to a mainstream therapy.

Observation:

• The 7+3 protocol, combining cytarabine and daunorubicin, has demonstrated enduring efficacy in AML treatment.
• Despite advancements, the 7+3 regimen's core structure remains a cornerstone of AML therapy.
• Higher doses of daunorubicin are now considered safe and part of the standard of care.

Findings:

• The original 7+3 protocol achieved complete responses in a significant proportion of both previously untreated and treated AML patients.
• Subsequent attempts to improve upon the 7+3 regimen with additional agents have not consistently yielded superior outcomes.

Implications:

• The 7+3 protocol's longevity highlights its effectiveness and the challenges in improving upon its foundational approach for AML.
• The increasing use of hematopoietic cell transplantation signifies a major advancement in treating acute leukemias.
• Further research into AML subtypes may lead to more personalized and effective treatment strategies.